MeiraGTx Holdings plc
For the period ended Apr 16, 2026. Filed Apr 16, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Apr 16, 2026 · Filed Apr 16, 2026
Use the contents to explore the available documents and sections.
Contents
Recent Developments
On April 16, 2026, the Company announced positive 3-year data from the Company’s Phase 1 AQUAx clinical study of AAV-hAQP1 for the treatment of grade 2/3 radiation induced xerostomia.
Treatment was observed to be safe and well tolerated at each dose tested with no dose-limiting toxicity or treatment-related serious adverse events.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.